Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
May 24, 2017
Changing Millennial Preferences and the Death of the Blue Box?
Image Source: samantha celera. The widely-held thesis that the ultra-rich care more about status than function may be waning as convergence between the two ensue. Let's talk Tiffany and the ultra-luxury space. May 24, 2017
Pipeline Woes Continue to Plague Amgen
Image Source: kibbles_bits. The commercial viability of a biotech outfit’s pipeline can often determine the future path of the share price. Irrespective of the past performance, if a company cannot innovate, it will witness its competitive position erode, leading to an inevitable decline in revenue. The latest setback from the clinical labs continues to support a bearish stance on Amgen. May 23, 2017
Cracker Barrel Hits the Trifecta!
Image Source: Mike Mozart. Cracker Barrel increased its full-year earnings guidance, raised its regular dividend, and issued a special payout. The market was pleased. May 22, 2017
Investing Versus Speculating: Ford, GM, Tesla
Ford is making some changes at the top, but we still like General Motors. Tesla’s stock remains “uninvestable,” in our view. May 20, 2017
Shoe Retailing Stocks Stumble
The market didn’t like the smell of Foot Locker’s first-quarter report, released May 19. Finish Line and Dick’s Sporting Goods likely forewarned of trouble. May 20, 2017
Deere Runs! South America Not As Bad?
Deere’s equity is charging higher. Let’s look at the reasons why. Will Caterpillar follow? May 20, 2017
Walmart Comes Roaring Back; Target Is Still Suffering
Image Source: Mike Mozart. Walmart and Target have taken a few body blows from Amazon, but the fight is far from over. Walmart is executing much better than Target at the moment. May 18, 2017
Earnings Update on the Medical Devices Industry Featuring Zimmer Biomet, Edwards Lifesciences, and Intuitive Surgical
Image Source: Biomet Zimmer. The outperformance of the medical devices industry continues unabated in 2017. The momentum underscores that the steep sell-off in the second half of 2016 was likely an overreaction. We’re updating our previous take of Zimmer Biomet, along with a brief earnings update on Edwards Lifesciences and Intuitive Surgical. May 17, 2017
Volatility Spikes, Oh Cisco, the Mighty US Dollar, and More
Image Source: CBOE. Let’s talk about recent market events May 17. There’s a lot going on. May 17, 2017
Coherus Biosciences Begins the Process of Bringing a Humira Biosimilar to Market
Image Source: Drugs.com. The duration and validity of patents that back the intellectual property of drugs in the pharma/biotech industry underpin the group’s revenue stream. Once patent protection is lost, however, revenue from products typically nosedives as multi-source products come to market, undercutting their original price. The patent estate, in essence, bestows monopoly-like pricing power to Big Pharma. Once lost though, it becomes tough to replace. Let’s provide a quick update on the breaking Coherus Biosciences patent win.
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 201202203204205206207208209210211212213214215216217218219220 221222223224225226227228229230231232233234235236237238239240 241242243244245246247248249250251252253254255256257258259260 261262263264265266267268269270271272273274275276277278279280 281282283284285286287288289290291292293294295296297298299300 301302303304305306307308309310311312313314315316317318319320 321322323324325326327328329330331332333334335336337338339340 341342343344345346347348349350351352353next The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|